Following people with myelofibrosis over time in Europe
Observes adults with myelofibrosis across European centres through regular follow-up visits.
Plain-language title generated from the registry record
Registry title: Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Key facts
- Where
- Halle, Hanover, and Minden, GermanySee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06533813, who can take part
Where in Germany
- University Hospital Halle Department of Hematology/OncologyHalle, GermanyNot yet recruiting
- University Medicine HannoverHanover, GermanyTaking people
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of BochumMinden, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Trial code
- NCT06533813
- Record updated
- 9 July 2026
- Original description
Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.Read full original descriptionShow less
Clinical Epidemiology in Contemporary Patients With Myelofibrosis (ERNEST-3): A European LeukemiaNet (ELN) Observational Study
Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.
Inclusion: Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027; Age ≥ 18 years; Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives.
Exclusion: Concurrent participation to interventional clinical trials in MF; Diagnosis of early/prefibrotic primary myelofibrosis.